As RNA therapeutics have gained traction scientifically and clinically, the software tools to engineer them have been frustratingly limited. The design of these oligos, study of functional properties, and analysis of results requires an evolving solution that can adeptly handle both chemistry and biology workflows.
We are excited to introduce Benchling’s modern, unified, fully configurable, and easy-to-use solution that adapts to the rapidly evolving needs of RNA therapeutics R&D. Scientists can now design chemically modified oligonucleotides, standardize on syntax, centralize experimental results, and collaborate with teammates more effectively on a single platform. With Benchling, researchers creating cutting edge RNA therapeutics can bring these breakthrough therapies to market faster.
In this webinar, we discuss how cross-functional researchers working on hybrid RNA entities can:
- Design chemically modified oligonucleotides with ease
- Centralize experimental data for faster, contextually-relevant insights
- Collaborate with teammates focused on biology and chemistry effectively